A majority of cancer deaths are because of an uncontrolled relapse of the disease despite initial remission after therapy, asking for strategies to control tumour cells in the long term. Adoptive therapy with chimeric antigen receptor (CAR)-redirected T cells showed promising success in primary tumour elimination; the capacity of such engineered T cells to establish enduring tumour protection is currently a matter of discussion, in particular as most targeted 'tumour-associated antigens' are self-antigens. To address the issue in a clinically relevant model that closely mimics the human situation, we recorded rejection of carcinoembryonic antigen (CEA)-positive pancreatic tumours in the CEA transgenic mouse that expressed CEA as self-antigen in healthy cells of the gastrointestinal tract. Adoptive therapy with CD8 þ T cells, which were redirected by a CEA-specific, low-affinity CAR with CD3z endodomain, eliminated CEA þ tumours in a primary response; cured mice produced an efficient recall response in the long term towards CEA þ tumour cells upon rechallenge. Secondary tumour rejection was CEA specific, mediated by engineered T cells and did not require host T cells. No toxicity towards healthy tissues with CEA expression was recorded. Data indicate that adoptive therapy with engineered T cells can establish self-antigen-specific tumour protection in the long term without autoimmunity.
INTRODUCTION
Most current strategies in cancer therapy are capable of inducing primary remission of tumour lesions; however, the antitumour effect frequently remains transient, resulting in an uncontrolled relapse that contributes to the vast majority of cancer deaths. As loss of immune surveillance is thought to be crucial in promoting tumour relapse, 1 strategies are explored to restrict tumour progression by adoptive transfer of genetically modified T cells with engineered tumour specificity and prolonged persistence. The 'T-body' strategy is an application of this approach based on engineering T cells with a chimeric antigen receptor (CAR) of predefined specificity that mediates binding through an extracellular single-chain fragment of variable region (scFv) antibody and T-cell activation through the intracellular CD3z signalling domain with or without appropriate costimulation. 2, 3 Activated by antigen engagement, CAR-engineered T cells execute their effector functions in an antigen-restricted, major histocompatibility complex (MHC)-independent fashion by amplifying, secreting a panel of pro-inflammatory cytokines and eliminating target cells. Various preclinical models demonstrated the elimination of transplanted tumour lesions by adoptively transferred CAR T cells in a primary antitumour response. A number of clinical trials are currently under way using CAR-modified T cells in the therapy of various malignant diseases, 4 ,5 some of them producing remarkable primary antitumour responses. 6 The capacity of CAR T cells to prevent a tumour relapse, however, is still less explored. Prevention of relapse requires long-term persistence and maintained antitumour effector functions of adoptively transferred T cells; 7, 8 however, most trials showed limited expansion and rapid disappearance of modified T cells. A most recent trial targeting CD19 in the adoptive T-cell therapy of advance B-cell leukaemia produced antitumour efficacy in the long term using T cells engineered with a 4 --1BB-CD3z costimulatory CAR. 9 Moreover, the potential of T cells with another costimulatory CAR with CD28-z signalling domain to establish secondary tumour rejection in the immune-deficient mouse was reported. 10 Most preclinical studies, however, neglect that the targeted 'tumour-associated antigen' is mostly a self-antigen that is physiologically expressed on healthy tissues and to which the patient is tolerant. Moreover, cancer patients are experiencing the antigen in high doses and over long time during tumour development. As a consequence, adoptively transferred T cells redirected towards a self-antigen may be repetitively restimulated by antigen engagement and/or tolerized. In this context, it is unresolved whether secondary tumour protection can be established by CAR-modified T cells in the host with physiological expression of the targeted 'tumour-associated antigen' without inducing autoimmunity. The issue is of clinical significance and challenges the potential of adoptive T-cell therapy to control tumour growth in the long term in the tolerant host. To address the situation, we here used the carcinoembryonic antigen (CEA) transgenic (tg) mouse 11 that is immune competent and physiologically expresses CEA by epithelial cells of the gastrointestinal tract, closely reflecting the human situation. A CEA þ murine tumour was established in those mice by transplantation and CD3z CAR T cells with redirected specificity for CEA were adoptively transferred. After primary tumour elimination, engineered T cells maintained CEA specificity in the CEA tg mouse and established robust secondary tumour protection in the long term without the induction of autoimmunity.
RESULTS

To redirect mouse T cells towards CEA
þ tumours in the immunecompetent mouse, we engineered a fully murinized CAR with a CD3z signalling domain and binding specificity for CEA and CD30 for control (Figure 1a ). Upon retroviral gene transfer, mouse CD8 þ T cells expressed the respective CAR with high efficiencies (Figure 1b) . The CAR redirected T-cell activation in a CEA-restricted fashion as co-incubation of anti-CEA CAR T cells with CEA þ C15A3 tumour cells produced T-cell interferon-g (IFN-g) secretion and cytolysis of target cells, whereas no T-cell activation occurred when the engineered T cells were co-incubated with the parental CEA À MC38 tumour cells (Figure 1c ). T cells modified with a CAR of irrelevant specificity were not activated by C15A3 or MC38 cells.
Mice produced rapidly growing tumours upon subcutaneous (s.c.) transplantation of CEA þ C15A3 tumour cells (Figure 2a ). Co-incubated CD8 þ T cells with engineered anti-CEA CAR prevented outgrowth of CEA þ C15A3 tumours, whereas mice that received C15A3 tumour cells together with engineered T cells with irrelevant CAR or mock-modified T cells rapidly developed tumours. Data demonstrate that the CAR-mediated primary T-cell response efficiently eliminated co-inoculated tumour cells in a CEA-specific fashion. The T-cell antitumour response persisted at least for the short term as those mice that successfully eliminated tumour cells in a primary response rejected CEA þ C15A3 tumour cells upon challenge at day 17 ( Figure 2b ). Mice that were inoculated with tumour cells for the first time at that day as control developed progressively growing tumours.
To address whether CEA-specific tumour protection can be established in the long term in the CEA-tolerant host, we used CEA tg mice that expressed CEA on the luminal side of gastrointestinal epithelia and that were fully immune competent and tolerant to CEA. 11 Mice were first inoculated with engineered CD8 þ T cells with or without CEA-specific CAR, respectively, together with irradiated CEA þ C15A3 tumour cells to stimulate transferred engineered T cells. At day 95, mice were challenged for secondary tumour rejection by s.c. inoculation of a tumourigenic dose of , respectively. IFN-g in the culture supernatant after 48 h was monitored by enzyme-linked immunosorbent assay (ELISA). Cytotoxicity towards tumour cells was determined colorimetrically by a tetrazolium salt-based viability assay. Data represent the mean of triplicates; *Po0.05 using Student's t-test. The assay was repeated twice; a representative assay is shown.
viable C15A3 tumour cells. Mice that received anti-CEA CAR T cells for the primary response efficiently rejected CEA þ tumour cells in a secondary response, whereas mice that were pretreated with unmodified T cells rapidly developed tumours after secondary tumour challenge (Figure 3a) . Tumour protection was CEA specific as tumour growth of the parental CEA À MC38 cells was not prevented in both mouse cohorts (Figure 3b ). Mice that primarily received anti-CD30 CAR-modified T cells together with irradiated C15A3 tumour cells likewise produced tumours upon secondary challenge with CEA þ and CEA À tumour cells (Figure 3b ). CEA þ and CEA À tumour growth was also observed in mice that received unmodified or no T cells for the primary response. We conclude that adoptive transfer of anti-CEA CAR-engineered T cells established CEA-specific secondary tumour rejection in the long term in the CEA tg mouse.
To explore whether host T cells, in addition to the adoptively transferred T cells, participate in secondary tumour rejection, we eliminated host CD4 þ and CD8 þ T cells by depleting antibodies before adoptive transfer of engineered T cells (Figure 4a ). Anti-CEA CAR-engineered T cells were adoptively transferred into T-celldepleted mice. The T-cell-depleted mice that received adoptive cell therapy with anti-CEA CAR T cells efficiently executed CEA þ tumour rejection upon secondary challenge (Figure 4b ), indicating that host T cells were not required to mediate secondary tumour rejection. The response is CEA specific as anti-CD30 CAR T cells as control did not provide secondary tumour protection. The process, moreover, required long-term survival of engineered T cells as mice that received irradiated anti-CEA CAR T cells did not reject secondary tumour challenge.
We asked whether orthotopic CEA þ tumours can be eliminated in a primary response and produce secondary tumour protection in the long term in the CEA-tolerant mouse. T cells transferred to CEA tg mice after ex vivo engineering with the respective CAR were of CD4 þ and CD8 þ subset and exhibited central memory (T CM ) or effector memory (T EM ) phenotype with moderately increased frequencies of T CM cells compared with unmodified T cells (Figure 5a ). Pancreatic carcinomas were induced in CEA tg mice by intrapancreatic injection of the murine CEA þ Panc02 tumour cells producing an orthotopic mouse pancreatic carcinoma with CEA expression. Tumour progression after tumour cell installation was monitored by bioluminescence recording of click beetle luciferase-marked tumour cells. When tumours were clearly established, anti-CEA CAR-engineered T cells were systemically administered by tail vain injection. As shown in Figure 5b , CEA þ Panc02 pancreatic tumours were controlled in 5/6 mice. To explore whether host T cells are involved in the process, pancreatic carcinoma-bearing mice were myeloablated by treatment with cyclophospamide and fludarabine before adoptive We assume that CAR-engineered T cells persist in those mice that cleared CEA þ pancreatic tumours in a primary response. Anti-CEA CAR T cells can specifically be detected by reverse transcriptase-PCR using primer oligonucleotides specific for the unique scFv domain of the CAR. As summarized in Figure 5d , anti-CEA CAR-engineered T cells were detected in the lung, spleen and pancreas of treated mice but only at background levels in peripheral blood and small and large intestines. The calculated number of anti-CEA CAR T cells in those organs remained the same before and after secondary tumour cell challenge. Detection of CAR-modified T cells was specific as anti-CEA CAR T cells were not recorded in mice treated with anti-CD30 CAR T cells as controls.
As CEA tg mice expressed CEA on luminal epithelia of the gastrointestinal tract and in lung, we asked whether long-term, CEA-specific tumour protection is associated with autoimmunity towards epithelia in these organs. Histology screening of tissues from CEA tg mice treated with anti-CEA or anti-CD30 CAR T cells as control did not reveal signs of major tissue destruction (Figure 5e , left panel). No organ damage, in particular in the lung and small and large intestines, was recorded. In line with that, no major or continuing weight loss of treated mice was recorded. In the pancreas of mice treated with anti-CEA CAR T-cell therapy, residual small carcinoma islets were detected along with substantial lymphocyte infiltrates, the latter lacking in mice treated with anti-CD30 CAR T cells. Taken together, histology screenings did not reveal signs of autoimmune destruction of CEA þ healthy tissues in the CEA tg mouse after adoptive therapy with anti-CEA CAR T cells.
However, small and large intestine tissues as well as the lung were infiltrated with anti-CEA CAR T cells as revealed by multicolour immune screening for CAR T cells (Figure 5e , right panel). Infiltrates with CD3 þ T cells with CAR expression were detected in these organs of mice treated with anti-CEA CAR T cells, whereas adoptive therapy with anti-CD30 CAR T cells did not produce CAR T-cell infiltrates, moreover implying that the T-cell accumulation is driven by the anti-CEA CAR. Taken together, anti-CEA CAR T-cell therapy produced infiltrations with engineered T cells in CEA þ healthy tissues, but without apparent tissue damage in the CEA tg mouse.
DISCUSSION
The establishment of tumour antigen-specific memory is thought to be crucial to control the disease and to prevent relapse in the long term. Although some reports document secondary tumour rejection by CAR-modified T cells in the immune-deficient host, 10 few data are so far available in a clinically relevant model that take into account that most targeted antigens on tumour cells are selfantigens that are physiologically expressed by healthy tissues. Two consequences thereof are that tumour patients are tolerant for the CAR-targeted antigen and that self-antigen targeting by CARengineered T cells may produce autoimmune pathology. To address the issue in an experimental system under these conditions, we took advantage of the CEA tg mouse that is immune competent, shows physiological CEA expression on 
We here demonstrated that adoptive transfer of anti-CEAredirected T cells established a specific recall response and secondary tumour protection in the long term. Secondary rejection required primary CAR-driven activation of T cells, was CEA specific and defined by the CAR as T cells engineered with a CAR of irrelevant specificity or nonmodified T cells did not provide protection against CEA þ tumour cells. Accordingly, CEA À tumour cells were not rejected whereas the same mouse was protected against tumour formation by the CEA þ derivative tumour cells. CAR-mediated T-cell activation in a primary antitumour response is critical for the effect as co-inoculation of CEA-specific T cells with irradiated CEA À cells, which does not induce CAR activation, did not produce secondary tumour cell rejection.
The results are of particular relevance as they indicate the establishment of a long-lasting memory by adoptive transfer of CD3z CAR-engineered T cells, and the self-antigen specificity of the secondary response as defined by the CAR. Data are moreover significant as secondary tumour protection was produced in the immune-competent, antigen-tolerant host without prior myeloablation.
Antigen-specific secondary tumour rejection was also reported using the Her-2/neu transgenic mouse as a model that expressed human Her-2/neu as self-antigen in healthy brain and mammary tissues. 12 Long-term persistence of adoptively transferred T cells correlates with clinical response as reported for the transfer of tumourinfiltrating lymphocytes in melanoma patients. 7 We likewise expect that durable persistence of CAR-modified T cells is required for lasting therapeutic success. Secondary CEA-specific tumour rejection is strong evidence that adoptively transferred CAR T cells persist in a functionally active manner in the CEA tg mouse for at least 3 months after primary tumour rejection. During that time, repetitive CAR stimulation may sustain T-cell persistence when Long-term antigen-specific tumour protection M Chmielewski et al encountering physiologically expressed CEA on healthy cells; the same situation may exist when T cells with specificity for another self-antigen are adoptively transferred. Our assumption is sustained by the moderate infiltration of anti-CEA CAR T cells in the CEA þ colon villi and the lung that was not observed upon transfer of CAR T cells of irrelevant specificity.
After adoptive therapy a number of mechanisms limit the persistence of modified T cells in vivo. CAR-engineered T cells may be recognized and eliminated by host immune cells recognizing the CAR as foreign antigen. We here used a CAR that entirely consists of murine domains; the fully humanized homologue with a humanized binding domain was previously reported by our group. 13 Joining regions within the recombinant protein, however, may still be immunogenic.
Moreover, T-cell persistence requires appropriate T-cell costimulation during activation that is provided by CARs containing the CD28 and 4-1BB costimulation domain. 8, 14 In a recently reported trial, CAR-mediated 4-1BB costimulation sustained persistence of engineered T cells in the peripheral blood; modified T cells were of T CM and T EM phenotypes that likely contributed to long-term survival of cells in a lymphodepleted environment. 9 Moreover, 4-1BB signalling, in the context of T-cell receptor engagement, promotes memory T-cell development. The CAR used in our study did not provide costimulatory signals and the target cells did not provide costimulatory ligands to trigger memory cell development. Although CD3z CAR T cells obviously can establish long-term memory as shown here, appropriate costimulation may substantially improve the effect.
Nonmyeloablative lymphodepletion prior adoptive therapy is considered to sustain T-cell persistence by providing both space and cytokines required for extensive T-cell amplification. 15 In the model used here lymphodepletion was not required to maintain the CAR-driven T-cell response for at least 3 months. We assume that this is the case as long as the CAR restimulates engineered T cells by targeting a self-antigen that is present in healthy cells, although in low densities compared with tumour cells.
Redirected T-cell activation in vivo is required to establish tumour protection in the long term, which became obvious when anti-CEA CAR T cells failed to establish long-term protection when not applied together with CEA þ tumour cells mimicking the primary anti-tumour response. The observation is in accordance to a previous report that T-cell receptor-modified T cells require in vivo activation for persistence in the wild-type mouse. 16 Engineered T cells capable of secondary tumour cell rejection are assumed to recirculate and penetrate tissues as specific guardians in order to eliminate spreading tumour cells and micrometastases. The assumption is sustained by our observation that secondary tumour rejection occurred at different sites than the primary tumour lesion; the primary carcinoma lesion was in the pancreas, whereas the secondary tumour challenge was performed by subcutaneous applications. The data are in accordance to observations reported for the Her-2/neu transgenic mouse model. 10 However, tumour lesions that lack the target antigen will not be recognized as demonstrated by secondary challenge with CEA À tumour cells that formed progressively growing tumours despite rejection of CEA þ tumour cells in the same mouse. Host T cells seem not to be required to establish a secondary tumour recall response as antibody-mediated depletion did not affect tumour rejection. At least 3 months lasting, transient depletion of host T cells is a caveat of the experimental design; however, similar conclusions were drawn from a severe combined immunodeficiency (SCID) mouse model with persistent absence of host T cells. 17 There are several aspects that need to be considered when translating mouse models of secondary tumour rejection into the clinical situation, in particular the T-cell dose and T-cell subset. We transferred 5 Â 10 5 CAR-engineered CD8 þ T cells per mouse in a single dose in a series of T-cell therapy assays. Assuming a CD8 þ T-cell pool of 2 Â 10 7 cells in the mouse and 2 Â 10 11 cells in humans, the transferred dose is equivalent to 5 Â 10 9 modified T cells in humans, which is about a single dose applied in current trials. 8 Even lower numbers as 10 7 engineered T cells, however, seem to be therapeutic in a trial as most recently reported. 6, 9 Maximal primary antitumour response in the immune-deficient mouse was achieved by transfer of equivalent numbers of CD4 þ and CD8
þ T cells compared with either T-cell subset alone, 17, 18 although CD8 þ T cells alone are sufficient to mediate primary antitumour effects in a number of other models. 19, 20 Although CAR-engineered CD8 þ T cells are also capable of establishing potent secondary tumour rejection in the immune-competent host as shown here, CD4
þ T-cell help, particularly mediated through T H 1-polarized CD4 þ T cells, sustains memory development and improves secondary tumour rejection. 10, 12, 17 Various other strategies may be applied to boost the generation of CAR-defined memory, including the application of irradiated, antigen-expressing target cells or vaccination with an antiidiotypic antibody that mimics the antigenic epitope of the CARbinding domain and thereby stimulates engineered T cells. 21 Moreover, co-application of engineered T cells with antigenpulsed dendritic cells exhibits a synergistic effect. 22 The strategy has the advantage of presenting a broad range of antigens provided by tumour cells to boost the antitumour response. T-cellmediated cytolysis in that model was MHC class I restricted and defined by the idiotype peptide. CAR-mediated T-cell memory, in contrast, has the advantage of being MHC unrestricted and defined by the antibody-derived CAR-binding domain with the consequence; however, a tumour relapse by antigen-loss tumour cell variants is not recognized. A recently described approach to activate the innate immune response by interleukin-12 (IL-12) delivering CAR T cells may provide a strategy to control those tumour cells. 23 
MATERIALS AND METHODS
Cell lines
293T cells are human embryonic kidney cells that express SV40 large T antigen. MC38 is a CEA-negative mouse adenocarcinoma cell line, C15A3 is a derivative of MC38 cells that expresses CEA upon transfection (kindly provided by Dr M Neumaier, Universitaetskliniken Heidelberg-Mannheim, Mannheim, Germany).
24 C15A3 cells were grown in the presence of 0.5 mg ml --1 G418 (Sigma-Aldrich, Taufkirchen, Germany). Panc02 is a tumourigenic murine pancreatic tumour cell line. 25 The CEA þ Panc02 cells were derived from Panc02 cells by transfection with a plasmid encoding human CEA (kindly provided by Dr David Gilham, University of Manchester, Manchester, UK). Panc02, C15A3 and MC38 cells were cultured in RPMI-1640 medium supplemented with 10% (v/v) heat-inactivated fetal calf serum (FCS) (Biochrom KG, Berlin, Germany), 2 mM L-glutamine (Gibco/BRL, Eggenheim, Germany), 50 IU ml --1 penicillin and 50 mg ml --1 streptomycin (Merck, Darmstadt, Germany). Mouse CD8 þ T cells were cultured in RPMI-1640 medium, Dutch modification, supplemented with sodium bicarbonate, 20 mM HEPES, 10% (v/v) heat-inactivated FCS (Biochrom), 2 mM L-glutamine, 2 mM sodium-pyruvate, 0.2 mM non-essential amino acids, 55 mM b-mercaptoethanol (all from Gibco/BRL), 50 IU ml --1 penicillin (Merck) and 50 mg ml --1 streptomycin (Merck).
Magnetic-activated cell sorting T cells were isolated from spleens, washed with cold phosphate-buffered saline containing 0.5% (w/v) bovine serum albumin, 1% (v/v) FCS, and 2 mM EDTA and incubated with immunomagnetic beads conjugated with anti-mouse CD8 antibody (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). CD8 þ T cells were positively enriched by magnetic-activated cell sorting procedures using an AutoMACS device (Miltenyi Biotec). The purity of isolated CD8 þ T cells was routinely 498% as monitored by flow cytometry.
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Generation of murine CARs
The complementary DNAs (cDNAs) for the mouse intracellular CD3z domain were generated from spleen RNA using RNeasy (Qiagen GmbH, Hilden, Germany). First-strand cDNA was synthesized using omniscript and Oligo(dT) 12À18 primer oligonucleotides (Qiagen). The CD3z cDNA was amplified from the cDNA pool using the oligonucleotide primer 5 Pancreatic carcinoma mouse model CEA tg C57BL/6 mice were obtained from the Patterson Institute. 8 The CEA tg mice colony was bred and maintained by back-crossing with a colony of C57BL/6N mice (Charles River, Wilmington, MA, USA). Offspring mice were genotyped by PCR of tail DNA using the primer oligonucleotides PJK GmbH, Kleinblittersdorf, Germany) as a substrate for the CB using a Photon Imager (Biospace Lab, Paris, France). The exposure time was 300 s for all recordings. The threshold of bioluminescence signals was automatically determined using the Photo Vision software (Biospace Lab). Bioluminescence signals were accordingly filtered. Regions of interest (ROIs) were defined as regions above threshold and automatically gated by appropriate programme tools. There was no manual gating of ROIs in order to avoid any incoherence. Photon emission intensity (photon/time) was calculated from data of emitted photons from the respective ROI using the Photo Vision software.
Recording CAR-engineered T cells
The distribution of CAR-engineered T cells in tissues of mice after adoptive T-cell therapy was analysed by reverse transcriptase-PCR. RNA from lung, spleen, pancreas and large and small intestines of mice was isolated using the 'Rneasy' kit (Qiagen). RNA was reversely transcribed into cDNA using of the 'one-step RT-PCR kit' (Qiagen) and the CAR-specific primer oligonucleotides SCA431-sense 5 0 -AAACAAACTGGAATGGATGGGCTACA-3 0 and SCA431-antisense 5 0 -AACGTGGGATAACTACTCCACTGAT-3 0 . cDNA obtained from reverse transcription of RNA from a known number of T cells with anti-CEA CAR was used as standard to estimate the number of CAR T cells in tissues of treated mice on the basis of cDNA band intensities. Upon electrophoresis, the intensity of the ethidium bromide-stained cDNA band was recorded by digital imaging of the ROI. The mean luminance intensity per ROI was automatically quantified using the ImageJ software (US National Institutes of Health, Bethesda, MD, USA).
